Get started
Author

Lisa Rodríguez

Observed name: Lisa Rodriguez
ORCID: 0000-0001-6417-0656
Observed ORCID: 0000-0001-6417-0656
OpenAlex ID: A5003080414
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
2021 · Leigh Marcus, Lola A. Fashoyin-Aje, et al. · Clinical Cancer Research · 616
PDF
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring BRAF V600E Mutations
2018 · Lauretta Odogwu, Luckson Mathieu, et al. · The Oncologist · 227
PDF
FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma
2020 · Sandra J. Casak, Martha Donoghue, et al. · Clinical Cancer Research · 187
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions
2020 · Diana Bradford, Erin Larkins, et al. · Clinical Cancer Research · 172
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer
2021 · Luckson Mathieu, Sujay Shah, et al. · The Oncologist · 157
PDF
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib
2021 · May Tun Saung, Lorraine Pelosof, et al. · The Oncologist · 111
PDF
FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma
2020 · Abhilasha Nair, Kelie Reece, et al. · The Oncologist · 94
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures
2023 · Madeline Pe, Ahu Alanya, et al. · The Lancet Oncology · 73
PDF
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation
2017 · Lauretta Odogwu, Luckson Mathieu, et al. · The Oncologist · 69
FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non–small Cell Lung Cancer, A Collaborative Project Orbis Review
2021 · Paz J. Vellanki, Flora Mulkey, et al. · Clinical Cancer Research · 60
FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial
2022 · E Dianne Pulte, Haiyan Chen, et al. · The Oncologist · 45
PDF
FDA's Approval of the First Biosimilar to Bevacizumab
2018 · Sandra J. Casak, Steven J. Lemery, et al. · Clinical Cancer Research · 39
Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
2018 · Lorraine Pelosof, Steven Lemery, et al. · The Oncologist · 24
Global Landscape of Benefit–Risk Considerations for Medicinal Products: Current State and Future Directions
2022 · Max Waschbusch, Lisa Rodriguez, et al. · Pharmaceutical Medicine · 4
A Survey to Assess the Current Status of Structured Benefit-Risk Assessment in the Global Drug and Medical Device Industry
2024 · Martin Gebel, Cheryl Renz, et al. · Therapeutic Innovation & Regulatory Science · 3
PDF
Key Opinion Leaders’ Interviews to Inform the Future of Benefit–Risk Planning in the Medical Total Product Life Cycle of Global Pharmaceutical and Medical Device Organizations
2024 · Arianna Simonetti, Susan Colilla, et al. · Drug Safety · 2
Supplementary Data from FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions
2023 · Diana Bradford, Erin Larkins, et al.
Data from FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions
2023 · Diana Bradford, Erin Larkins, et al.
Works count: 18
Citation count: 1,883
H-index: 13
I10-index: 13
Year
Topic
Type